Table 2.
Prevalence of sinonasal symptoms in MwoA.
| Symptom | Symptom present in headache phase n = 1,679 (%) |
Location in respect to pain n (%) |
Symptom present in headache-free phase n = 1,679 (%) |
|---|---|---|---|
| Clear/watery nasal discharge (anterior) (rhinorrhea) | 303 (18.1) | Bi. 194 (11.6) Ipsi. 101 (6.0) Con. 8 (0.5) |
367 (21.7) |
| Mucopurulent nasal discharge (anterior) | 70 (4.2) | Bi. 58 (3.5) Ipsi. 9 (0.5) Con. 3 (0.2) |
77 (4.6) |
| Nasal discharge (posterior) | 219 (13.0) | NA | 356 (21.2) |
| Nasal congestion | 396 (23.6) | Bi. 241 (14.4) Ipsi. 149 (8.9) Con. 6 (0.4) |
343 (20.4) |
| Facial pressure | 792 (47.2) | Bi. 195 (11.6) Ipsi. 581 (34.6) Con. 16 (1.0) |
269 (16.0) |
| Facial tenderness to palpation | 743 (44.3) | Bi. 255 (15.2) Ipsi. 474 (28.2) Con. 14 (0.8) |
235 (14.0) |
| Hyposmia / anosmia | 182 (10.8) | NA | 120 (7.2) |
| Osmophobia | 1,113 (66.3) | NA | 310 (18.5) |
| RS symptoms fulfilling clinical EPOS 2020 diagnostic criteria | 341 (20.3) | NA | 213 (12.7) |
Bi – bilateral, Ipsi. – ipsilateral, Con. – contralateral, NA- not applicable, RS – rhinosinusitis, EPOS - European Position Paper on Rhinosinusitis and Nasal Polyps 2020.